A multi-epitope peptide of largemouth bass frog iridovirus and its preparation method and application

Through screening and tandem formation of multi-epitope peptides ME-pep1 and ME-pep2 vaccines, the problem of poor immunity of single antigen epitope vaccines was solved, significantly improving the immune protection rate and immune-related indicators of largemouth bass, providing More effective methods to prevent and control largemouth black bass frog iridescent virus.

CN118580320BActive Publication Date: 2024-11-26SHENZHEN WANKESEN BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411059791.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-26
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

In the prevention and treatment of largemouth bass frog iridescent virus, the immune effect of single antigen epitope vaccine is poor, and the excessive use of chemical drugs leads to food and environmental safety problems. There is a lack of mature multi-epitope peptide vaccine for effective prevention and treatment.

Method used

By screening out 6 B cell epitopes and CTL epitopes, the multi-epitope peptides ME-pep1 and ME-pep2 were formed in a specific order, and the multi-epitope peptide vaccine was prepared and intraperitoneal injection was performed. Immune to improve the immune protection rate of largemouth bass.

Benefits of technology

It significantly improves the serum antibody titer, immune-related physiological indicators and relative immune protection rate of largemouth bass, reduces the side effects of the vaccine, provides a more comprehensive and lasting immune response, and improves the prevention and treatment effect of largemouth bass frog iridescent virus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118580320B_ABST
    Figure CN118580320B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and discloses a multi-epitope peptide of largemouth bass frog iridovirus, and a preparation method and application thereof. The present invention uses technical means such as immunoinformatics and genetic engineering to screen out the dominant CTL epitopes and B cell epitopes of the major capsid protein of largemouth bass frog iridovirus (LMBV), connects each epitope through a linker to obtain multi-epitope peptides ME‑pep1 and ME‑pep2, and then couples them with hemocyanin and mixes them with an adjuvant to prepare a multi-epitope peptide vaccine. Experiments have shown that the multi-epitope peptide vaccine prepared by ME‑pep1 and ME‑pep2 has a relative immune protection rate of 60.71% and 67.86% for largemouth bass infected with LMBV, respectively, which is higher than other groups. The present invention connects multiple single antigen epitopes in series, excludes immune-irrelevant components or immune-tolerant components, and has an important contribution to reducing vaccine side effects and enhancing vaccine protective efficacy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to a multi-epitope peptide of a largemouth bass frog iridovirus and a preparation method and application thereof. Background Art

[0002] Largemouth bass ( Micropterus salmoides ) is one of the important economic fish species that are widely farmed. However, with the continuous development of intensive farming, the largemouth bass farming industry is facing severe challenges from frequent diseases. Among them, the mortality rate of viral diseases caused by Largemouth bass ranavirus (LMBV) can reach more than 70%, which seriously threatens the healthy development of the largemouth bass farming industry.

[0003] Largemouth bass frog iridovirus belongs to the family Ranaviridae ( Iridoviridae ) Ranavirus Ranavirus ), is a double-stranded DNA virus with an icosahedral structure, a diameter of about 150~170nm, a genome size of 100~210kbp, and a major capsid protein (MCP) molecular weight of 48~55kDa. MCP is often used in LMBV vaccine preparation due to its strong immunogenicity.

[0004] At present, LMBV prevention and control still relies on chemical drugs, but drug residues caused by excessive use of chemical drugs will cause problems such as food and environmental safety. Vaccination is an effective means to prevent and control fish diseases and an effective way to reduce the use of chemical drugs. The applicant previously used phage display technology to screen out 6 B cell antigen epitopes of MCP protein. The antigen epitope vaccine constructed based on this can induce largemouth bass to produce specific antibodies and provide significant protection. However, the immune response caused by the single antigen epitope vaccine is weak and the immune effect is poor.

[0005] Multi-epitope peptide vaccines are new vaccines made of multiple protective antigen epitopes. In addition to good safety and strong specificity, their greatest advantage is that they can exclude non-immune related components or immune tolerance components in antigen molecules, regulate the type of immune response, thereby greatly reducing vaccine side effects and enhancing immune protection. However, there is currently no successful and mature multi-epitope peptide vaccine for largemouth bass. Therefore, the development of multi-epitope peptide vaccines to achieve safe and effective prevention and treatment of largemouth bass LMBV is an urgent problem to be solved. Summary of the invention

[0006] In order to further improve the prevention and treatment effect of LMBV on largemouth bass, the applicant connected the six B cell epitopes pep1-pep6 screened in the early stage with the CTL epitope in a specific order, thereby further improving the prevention and treatment effect of the existing single antigen epitope. In order to achieve this technical purpose, the present invention provides the following detailed technical solutions.

[0007] On the one hand, the present invention provides a multi-epitope peptide of largemouth bass frog iridovirus, wherein the multi-epitope peptide is ME-pep1, wherein the ME-pep1 is obtained by connecting Pep2, Pep3, Pep5, and Pep6 in series by a GPGPG connecting peptide, and the connection sequence is: pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3. Or the multi-epitope peptide is ME-pep2, wherein the ME-pep2 is obtained by connecting ME-pep1 with CT1, CT2, CT3, and CT4 in series by an AAY connecting peptide, and the connection sequence is: CT1-connecting peptide-CT2-connecting peptide-CT3-connecting peptide-CT4-connecting peptide-ME-pep1.

[0008] Among them, the amino acid sequence of the CT1 is shown in SEQ ID NO:1; the amino acid sequence of the CT2 is shown in SEQ ID NO:2; the amino acid sequence of the CT3 is shown in SEQ ID NO:3; the amino acid sequence of the CT4 is shown in SEQ ID NO:4; the amino acid sequence of the pep2 is shown in SEQ ID NO:5; the amino acid sequence of the pep3 is shown in SEQ ID NO:6; the amino acid sequence of the pep5 is shown in SEQ ID NO:7; and the amino acid sequence of the pep6 is shown in SEQ ID NO:8.

[0009] Further, the preparation method of ME-pep1 is:

[0010] 1) Screening of CTL epitopes: predict the CTL epitopes of the major capsid protein of the largemouth bass frog iridovirus, and screen out the four CTL epitopes with the highest scores: CT1, CT2, CT3 and CT4;

[0011] 2) Screening of B cell epitopes: Based on phage display and bioinformatics technology, the B cell epitopes of the major capsid protein of the largemouth bass frog iridovirus were identified, and the four B cell epitopes pep2, pep3, pep5 and pep6 with the best immune effect were screened out through in vivo experiments;

[0012] 3) Obtaining ME-pep1: ME-pep1 was obtained by connecting the connecting peptides in the order of pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3; the connecting peptide used to prepare ME-pep1 was GPGPG.

[0013] The preparation method of the ME-pep2 is:

[0014] 1) Screening of CTL epitopes: predict the CTL epitopes of the major capsid protein of the largemouth bass frog iridovirus, and screen out the four CTL epitopes with the highest scores: CT1, CT2, CT3 and CT4;

[0015] 2) Screening of B cell epitopes: Based on phage display and bioinformatics technology, the B cell epitopes of the major capsid protein of the largemouth bass frog iridovirus were identified, and the four B cell epitopes pep2, pep3, pep5 and pep6 with the best immune effect were screened out through in vivo experiments;

[0016] 3) Obtaining ME-pep1: Use connecting peptides in the order of pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3 to obtain ME-pep1; the connecting peptide used to prepare ME-pep1 is GPGPG;

[0017] 4) Obtaining ME-pep2: ME-pep2 was obtained by connecting the connecting peptides in the order of CT1-connecting peptide-CT2-connecting peptide-CT3-connecting peptide-CT4-connecting peptide-ME-pep1; the connecting peptide used to prepare ME-pep2 was AAY.

[0018] Finally, the present invention also claims to protect the use of the multi-epitope peptide in the preparation of fish virus prevention and treatment drugs, wherein the multi-epitope peptide is used to prepare a multi-epitope peptide vaccine against largemouth bass frog iris virus.

[0019] Furthermore, in the above application, the preparation method of the multi-epitope peptide vaccine is:

[0020] 1) Conjugating the multi-epitope peptide ME-pep1 or ME-pep2 to hemocyanin to obtain a multi-epitope peptide-KLH conjugate;

[0021] 2) dissolving the multi-epitope peptide-KLH conjugate in sterile water to prepare a multi-epitope peptide-KLH conjugate solution with a concentration of not less than 2 mg / mL;

[0022] 3) The multi-epitope peptide-KLH conjugate solution is mixed with the same volume of Freund's adjuvant and emulsified to obtain.

[0023] Furthermore, in the above application, the multi-epitope peptide vaccine is administered by injection, and the dose of injection is 10 μg / g.

[0024] Furthermore, in the above application, after injection immunization, the specific antibody level of largemouth bass is increased.

[0025] Furthermore, in the above application, after injection immunization, the alkaline phosphatase activity, acid phosphatase activity, total antioxidant capacity and superoxide dismutase activity of largemouth bass are increased.

[0026] Furthermore, in the above application, the relative immune protection rate of largemouth bass is improved.

[0027] Compared with the prior art, the present invention "a multi-epitope peptide of largemouth bass frog iridovirus and its preparation method and application" has at least the following beneficial effects:

[0028] The present invention uses the connecting peptide GPGPG to connect four preferred B cell epitopes to obtain ME-pep1; ME-pep1 is connected to four preferred CTL epitopes using the AAY linking peptide to obtain the multi-epitope peptide ME-pep2. After analysis, the multi-epitope peptides ME-pep1 and ME-pep2 have relatively independent epitopes and good antigenic parameters, and have the potential to be further prepared into multi-epitope peptide vaccines.

[0029] The multi-epitope peptide vaccine prepared based on ME-pep1 and ME-pep2 was then intraperitoneally injected into largemouth bass for immunization. The serum antibody titer reached a peak on the 21st day, and the serum antibody titer of the multi-epitope peptide vaccine prepared with ME-pep2 was the highest, indicating that the multi-epitope peptide vaccine can induce a strong immune response in largemouth bass.

[0030] In addition, the multi-epitope peptide vaccine can significantly increase the alkaline phosphatase activity, acid phosphatase activity, total antioxidant capacity and superoxide dismutase activity of largemouth bass. The changes in these immune-related physiological indicators further prove that the multi-epitope peptide vaccine improves the body's immune level of largemouth bass.

[0031] Finally, the present invention also detected the relative immune protection rate of the multi-epitope peptide vaccine after LMBV infection. The relative immune protection rates of the multi-epitope peptide vaccines prepared with ME-pep1 and ME-pep2 for largemouth seabass were 60.71% and 67.86%, respectively, which were higher than those of the MCP group and PBS group, and were further improved compared with the existing patent CN118324901A, with significant results.

[0032] The present invention connects multiple single antigen epitopes in series, excluding immune-irrelevant components or immune-tolerant components, which has an important contribution to reducing vaccine side effects and enhancing vaccine protective efficacy. The multi-epitope peptide vaccine provided by the present invention can provide a more comprehensive and lasting immune response for largemouth bass, improve the prevention effect of largemouth bass frog iridovirus disease, and provide reference basis and technical support for the creation of fishery vaccines for other viral diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1It is a concatenation mode of multi-epitope peptide ME-pep1.

[0034] Figure 2 It is a tandem form of the multi-epitope peptide ME-pep2.

[0035] Figure 3 The results of hydrophilicity, antigenicity and surface accessibility analysis of the multi-epitope peptide ME-pep1.

[0036] Figure 4 The results of hydrophilicity, antigenicity and surface accessibility analysis of the multi-epitope peptide ME-pep2.

[0037] Figure 5 The serum antibody titers of each treatment group on days 7, 14, 21, and 28 after immunization.

[0038] Figure 6 This is the alkaline phosphatase (AKP) activity level on the 21st day after immunization with the multi-epitope peptide vaccine.

[0039] Figure 7 It is the acid phosphatase (ACP) activity level on the 21st day after immunization with the multi-epitope peptide vaccine.

[0040] Figure 8 This is the total antioxidant capacity (T-AOC) on the 21st day after immunization with the multi-epitope peptide vaccine.

[0041] Fig. 9 This is the superoxide dismutase (SOD) activity level on the 21st day after immunization with the multi-epitope peptide vaccine. DETAILED DESCRIPTION

[0042] The present invention is explained below in conjunction with the embodiments, and the technical solutions in the embodiments of the present invention are clearly and completely described. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] Information on test materials used in the examples:

[0044] Largemouth bass (1.9±0.4 g, 4.5±0.7 cm) were cultured in the laboratory recirculating aquaculture system for two weeks at the Wanyue fish fry breeding base in Guangzhou, Guangdong Province. The experiment was conducted at a water temperature of 22±0.5°C. The largemouth bass frog iridovirus used in the example was the LMBV-FS001 strain (GenBank accession No.ON936874), which was preserved in this laboratory.

[0045] Example 1

[0046] This example describes CTL epitope prediction.

[0047] The NetCTL.1.2 server (http: / / www.cbs.dtu.dk / services / NetCTL) was used to predict cytotoxic T lymphocyte (CTL) epitopes from MCP proteins. CTLs destroy infected cells, and their activation usually occurs on the surface of antigen-presenting histocompatibility complex (MHC) molecules. The NetCTL.1.2 server integrates the prediction of MHC class I binding, proteasome C-terminal cleavage, and transport efficiency of transporter associated with antigen processing (TAP). Among them, artificial neural networks are used to predict MHC class I binding and proteasome C-terminal cleavage, and weight matrices are used to predict TAP transport efficiency. When predicting the CTL epitopes of MCP proteins, the amino acid sequence of MCP proteins is input, and MHC supertype A1 is used for prediction. The appropriate proteasome C-terminal cleavage parameters, TAP transport efficiency parameters, and epitope identification thresholds are selected, and the CTL epitope information is submitted and output.

[0048] CTL epitopes are potential candidates for vaccine design against various diseases. NetCTL.1.2 was used to predict CTL epitopes. MHC binding affinity, proteasome C-terminal cleavage affinity and transport affinity were used as scoring criteria. A total of 13 peptide sequences with scores > 0.7500 were identified as CTL epitopes. The scoring results are shown in Table 1.

[0049] Table 1. Prediction of CTL epitopes of MCP protein

[0050]

[0051] Example 2

[0052] This example describes the design of a multi-epitope peptide vaccine.

[0053] The four CTL epitopes with the highest scores and the four B cell epitopes (pep2, pep3, pep5 and pep6) of the MCP protein of the largemouth bass frog iridovirus that had been screened and identified in the early stage were selected to develop and construct a multi-epitope peptide vaccine. The amino acid sequences are shown in Table 2.

[0054] Table 2. Antigenic epitope amino acid sequences

[0055]

[0056] Each epitope is connected in series with a linker, and the four B cell epitopes are connected in series with a linker peptide GPGPG (glycine-proline-glycine-proline-glycine). The connected multi-epitope peptide is named ME-pep1, and the connection method is: pep6-linker peptide-pep5-linker peptide-pep2-linker peptide-pep3, see Figure 1.

[0057] ME-pep1 was connected to the four CTL epitopes using a connecting peptide AAY (alanine-alanine-tyrosine). The connected multi-epitope peptide was named ME-pep2. The concatenation method was: CT1-connecting peptide-CT2-connecting peptide-CT3-connecting peptide-CT4-connecting peptide-ME-pep1, see Figure 2 .

[0058] DNAstar Protean software was used to analyze the hydrophilicity, antigenicity and surface accessibility parameters. The analysis results are as follows: Figure 3 , Figure 4 .Depend on Figure 3 , Figure 4 It can be seen that the epitopes in the tandem multi-epitope peptides ME-pep1 and ME-pep2 are relatively independent, the antigenic parameters are good, and both are hydrophilic proteins.

[0059] Example 3

[0060] This example describes the construction of a multi-epitope peptide vaccine and the evaluation of its immune effect.

[0061] Preparation of multi-epitope peptide vaccine: ME-pep1 and ME-pep2 multi-epitope peptides were synthesized respectively, and hemocyanin (Keyhole Limpet Hemocyanin, KLH) was used as a carrier protein to couple the multi-epitope peptide with KLH to prepare a multi-epitope peptide-KLH conjugate, which was then dissolved in sterile water to prepare a multi-epitope peptide-KLH conjugate solution with a concentration of 2 mg / mL. The same volume of Freund's adjuvant as the solution was taken, and the multi-epitope peptide-KLH conjugate solution was added dropwise while vortexing to fully emulsify it to obtain a multi-epitope peptide vaccine.

[0062] Largemouth bass immunization: Largemouth bass were immunized by intraperitoneal injection, and the immunization dose was 10 μg / g. The experiment set up ME-pep2 immunization group, ME-pep1 immunization group, MCP immunization group, and PBS blank control group, with 50 fish in each group, and three parallel treatments were set.

[0063] Antibody level detection: Blood was collected on days 7, 14, 21 and 28 after immunization, and serum antibody titers were detected by indirect ELISA. The results were as follows: Figure 5 shown. Figure 5 It can be seen that except for the PBS blank control group, the serum antibody titers of largemouth bass in the other groups gradually increased after immunization, and reached a peak on the 21st day of immunization, and then decreased. Among all the groups, the serum antibody titer of the ME-pep2 immunization group was the highest.

[0064] Example 4

[0065] This example describes the detection of immune-related physiological indicators.

[0066] The serum from the 21st day of immunization in Example 3 was taken, and the enzyme activities of alkaline phosphatase (AKP), acid phosphatase (ACP), total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) in the serum were determined according to the instructions of the enzyme activity detection kit (Nanjing Jiancheng Bioengineering Institute).

[0067] Figure 6 , Figure 7 , Figure 8 , Fig. 9 The results of AKP, ACP, T-AOC and SOD determination of each group are shown respectively. Figures 6 to 9 It can be seen that for AKP, ACP, T-AOC, and SOD, the enzyme activity levels of the ME-pep2 immunization group were higher than those of the other groups, followed by the ME-pep1 group, the MCP immunization group, and the PBS blank control group.

[0068] Example 5

[0069] This example describes the relative immune protection rate of the multi-epitope peptide vaccine after LMBV infection.

[0070] After 28 days of immunization, 30 largemouth bass from each experimental group were randomly selected for LMBV infection test. LMBV virus solution (20 μL / fish, 10 5 TCID 50 / mL), record the incidence and survival of largemouth bass within 14 days, control the water temperature at 25±0.5℃ during the experiment, and keep other culture conditions unchanged to calculate the relative percentage survival (RPS). RPS calculation method:

[0071] RPS=(1-mortality rate of immunized group / mortality rate of control group)×100.

[0072] Table 3. Relative immune protection rate

[0073]

[0074] The experimental results are shown in Table 3. After 14 days of LMBV infection, the mortality rate of the PBS blank control group was 93.33%, the relative immune protection rate of the MCP immunization group was 53.57%, the relative immune protection rate of the ME-pep1 group was 60.71%, and the relative immune protection rate of the ME-pep2 group was 67.86%. The results indicate that the multi-epitope peptide vaccine prepared by ME-pep2 can provide better immune protection for largemouth bass.

[0075] The embodiments described above are only some embodiments of the present invention, not all embodiments. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.

Claims

1. A multi-epitope peptide of largemouth bass frog iridovirus, characterized in that: The multi-epitope peptide is ME-pep1, and the ME-pep1 is obtained by connecting Pep2, Pep3, Pep5, and Pep6 in series with a GPGPG connecting peptide, and the connection order is: pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3; Or the multi-epitope peptide is ME-pep2, and the ME-pep2 is obtained by connecting ME-pep1 with CT1, CT2, CT3, and CT4 in series by an AAY connecting peptide, and the connection order is: CT1-connecting peptide-CT2-connecting peptide-CT3-connecting peptide-CT4-connecting peptide-ME-pep1; The amino acid sequence of CT1 is shown in SEQ ID NO: 1; The amino acid sequence of CT2 is shown in SEQ ID NO: 2; The amino acid sequence of CT3 is shown in SEQ ID NO: 3; The amino acid sequence of CT4 is shown in SEQ ID NO:4; The amino acid sequence of pep2 is shown in SEQ ID NO:5; The amino acid sequence of pep3 is shown in SEQ ID NO:6; The amino acid sequence of pep5 is shown in SEQ ID NO:7; The amino acid sequence of pep6 is shown in SEQ ID NO:

8.

2. The multi-epitope peptide according to claim 1, characterized in that The preparation method of ME-pep1 is: 1) Screening of CTL epitopes: predict the CTL epitopes of the major capsid protein of the largemouth bass frog iridovirus, and screen out the four CTL epitopes with the highest scores: CT1, CT2, CT3 and CT4; 2) Screening of B cell epitopes: Based on phage display and bioinformatics technology, the B cell epitopes of the major capsid protein of the largemouth bass frog iridovirus were identified, and the four B cell epitopes pep2, pep3, pep5 and pep6 with the best immune effect were screened out through in vivo experiments; 3) Obtaining ME-pep1: ME-pep1 was obtained by connecting the connecting peptides in the order of pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3; the connecting peptide used to prepare ME-pep1 was GPGPG.

3. The multi-epitope peptide according to claim 1, characterized in that The preparation method of the ME-pep2 is: 1) Screening of CTL epitopes: predict the CTL epitopes of the major capsid protein of the largemouth bass frog iridovirus, and screen out the four CTL epitopes with the highest scores: CT1, CT2, CT3 and CT4; 2) Screening of B cell epitopes: Based on phage display and bioinformatics technology, the B cell epitopes of the major capsid protein of the largemouth bass frog iridovirus were identified, and the four B cell epitopes pep2, pep3, pep5 and pep6 with the best immune effect were screened out through in vivo experiments; 3) Obtaining ME-pep1: Use connecting peptides in the order of pep6-connecting peptide-pep5-connecting peptide-pep2-connecting peptide-pep3 to obtain ME-pep1; the connecting peptide used to prepare ME-pep1 is GPGPG; 4) Obtaining ME-pep2: ME-pep2 was obtained by connecting the connecting peptides in the order of CT1-connecting peptide-CT2-connecting peptide-CT3-connecting peptide-CT4-connecting peptide-ME-pep1; the connecting peptide used to prepare ME-pep2 was AAY.

4. Use of the multi-epitope peptide according to claim 1 in the preparation of fish virus prevention and treatment drugs, characterized in that: The multi-epitope peptide is used for preparing a multi-epitope peptide vaccine against largemouth bass frog iridovirus.

5. The use according to claim 4, characterized in that: The method for preparing the multi-epitope peptide vaccine against largemouth bass frog iridovirus is as follows: 1) Conjugating the multi-epitope peptide ME-pep1 or ME-pep2 to hemocyanin to obtain a multi-epitope peptide-KLH conjugate; 2) dissolving the multi-epitope peptide-KLH conjugate in sterile water to prepare a multi-epitope peptide-KLH conjugate solution with a concentration of not less than 2 mg / mL; 3) The multi-epitope peptide-KLH conjugate solution is mixed with the same volume of Freund's adjuvant and emulsified to obtain.

6. The use according to claim 5, characterized in that: The multi-epitope peptide vaccine is administered by injection, and the dosage of the injection is 10 μg / g.

7. The use according to claim 6, characterized in that: After injection immunization, the specific antibody level of largemouth bass increased.

8. The use according to claim 6, characterized in that: After injection immunization, the alkaline phosphatase activity, acid phosphatase activity, total antioxidant capacity and superoxide dismutase activity of largemouth bass increased.

9. The use according to claim 6, characterized in that: After injection immunization, the relative immune protection rate of largemouth bass increased.